Lilly reports novel diabetes drug win

Oct 05, 2018

Eli Lilly and Co. announced positive results in a mid-stage trial for its experimental new diabetes drug.

According to the drugmaker, the two-in-one drug significantly reduced blood sugar levels and promoted weight loss in patients with type 2 diabetes.

Good news for Lilly, as shares hit a record high, and bad news for rival Novo Nordisk, as the new drug could threaten to currently available single-hormone drugs, which form a large and growing part of Novo’s business.

Lilly’s late-stage trial for the dual GIP and GLP-1 receptor agonist is expected to be completed in 2021.

Read the press release

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments